In the case of molecules targeting CD19 on B cells, one cannot exclude a possible co-signal triggered by the interaction between CD28 and B7, known to be expressed on normal and malignant B cells. However, BiTE molecules targeting EpCAM expressed on a variety of solid tumor of epithelial origin that do not express B7 show similar efficacy.